News About: Pharm. Industry
Ex-KFDA director becomes Hanmi vice president
Kim Yeon-pan, former director of the Korea Food and Drug Administration, was named vice president of Hanmi Pharm, the company’s spokesperson said on February 4.
Kim, 62, will head three departments – development, c...
Ur to be renamed KPMA head
Ur Choon-sun, the incumbent chairman of the Korea Pharmaceutical Manufacturers Association, is likely to be renamed as the next chairman, according to sources.
In a meeting on February 5, the KPMA’s advisory commi...
Falling won affects drugmakers
The won's freefall against the dollar is taking a toll on the local pharmaceutical industry, which is suffering difficulties caused by the drastic decline in the local currency's value.
The combined turnover of 14...
Research-oriented pharmaceutical firms set eyes on overseas markets
Korea’s research based pharmaceutical firms – LG Life Sciences (LGLS), Hanmi Pharm, Ilyang Pharm, Dong-A Pharm and Donwha Pharm, are going all-out to make inroads into foreign countries as the domestic market shows cl...
National Pension Fund likely to make less investment in pharmaceutical shares
With the Capital Market Consolidation Act going into effect on February 4, experts said that the National Pension Fund will invest less in local pharmaceutical, fashion, papers and insurances shares.
Sources say th...
DreamCIS, ASKLEP signs strategic partnership agreement
DreamCIS Inc. Korea’s largest CRO and ASKLEP Inc. a Japan CRO, announced on January 30 that the two companies have signed a strategic partnership agreement to provide reciprocal clinical research services in their res...
Hong Um-ki named executive managing director of Abbott Korea
Abbott Korea, a Korean unit of Abbott Laboratories, said that it has appointed Hong Um-ki as a new executive managing director as of February 3.
Hong, 51, will be responsible for personal management affairs.
A g...
Health insurance covers Exelon patch
Novartis Korea said that Exelon Patch (rivastigmine transdermal patch), the first transdermal therapy for mild-to-moderate Alzheimer's disease, has been included in a list of insurance-covered medicines from February ...
Concerns growing over government’s price cut
There are mounting concerns over the government’s pressure to lower drug costs, although some large pharmaceutical firms, such as Yuhan Corporation, Hanmi Pharm, Green Cross Corporation and Chong Kun Dang Pharmaceutic...
Korean drugmakers urged to develop biosimilars
Domestic pharmaceutical firms will need to focus on development of promising biosimilars or similar biologics, considering the lack of money and resources to develop new drugs, according to market experts.
Unlike t...
